絞り込み

16641

広告

「"Schuchter LM "[Author]」の検索結果

115件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Machine Learning Approaches to Predict 6-Month Mortality Among Patients With Cancer.

Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.

Anti-CTLA4 activates intratumoral NK cells and combined with IL15/IL15R-alpha complexes enhances tumor control.

TOX transcriptionally and epigenetically programs CD8 T cell exhaustion.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma.

NRAS Q61R and BRAF G466A Mutations in Atypical Melanocytic Lesions Newly Arising in Advanced Melanoma Patients Treated with Vemurafenib.

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer.

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

Best Practices for Reducing Unplanned Acute Care for Patients With Cancer.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Adjuvant Melanoma Therapy - Head-Spinning Progress.

Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer.

A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります